Yuan Shiqin, Huang Xiaoyu, Zhang Shuang, Yang Shangying, Rui Xue, Qi Xiaolong, Wang Xuhui, Zheng Yali, Rong Weining, Sheng Xunlun
Ningxia Eye Hospital, People's Hospital of Ningxia Hui Autonomous Region, Third Clinical Medical College of Ningxia Medical University, Yinchuan, China.
Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Front Genet. 2023 Jan 27;14:1107347. doi: 10.3389/fgene.2023.1107347. eCollection 2023.
Donnai-Barrow syndrome (DBS) is a rare autosomal recessive disorder caused by mutation in the low density lipoprotein receptor-related protein 2 gene (). Defects in this protein may lead to clinical multiple organ malformations by affecting the development of organs such as the nervous system, eyes, ears, and kidneys. Although some variations on have been found to be associated with DBS, early diagnosis and prevention of patients with atypical DBS remains a challenge for many physicians because of their clinical heterogeneity. The objective of this study is to explore the association between the clinical presentation and the genotype of a DBS patient who was initially diagnosed with early-onset high myopia (eoHM) from a healthy Chinese family. To this end, we tested the patient of this family whole exome sequencing and further verified the results among other family members by Sanger sequencing. Comprehensive ophthalmic tests as well as other systemic examinations were also performed on participants with various genotypes. Genetic assessment revealed that two novel variations in , a missense variation (c.9032G>A; p.Arg3011Lys) and a novel splicing variation (c.2909-2A>T) inherited from the father, were both carried by the proband in this family, and they are strongly associated with the typical clinical features of DBS patients. Therefore, in this paper we are the first to report two novel compound heterozygous variations in causing DBS. Our study extends the genotypic spectrums for -DBS and better assists physicians in predicting, diagnosing, and conducting gene therapy for DBS.
多纳伊-巴罗综合征(DBS)是一种罕见的常染色体隐性疾病,由低密度脂蛋白受体相关蛋白2基因()突变引起。该蛋白的缺陷可能通过影响神经系统、眼睛、耳朵和肾脏等器官的发育,导致临床多器官畸形。尽管已发现该基因的一些变异与DBS相关,但由于非典型DBS患者的临床异质性,对许多医生来说,早期诊断和预防仍是一项挑战。本研究的目的是探讨一名最初被诊断为早发性高度近视(eoHM)的DBS患者的临床表现与基因型之间的关联,该患者来自一个健康的中国家庭。为此,我们对该家庭的患者进行了全外显子组测序,并通过桑格测序在其他家庭成员中进一步验证了结果。还对具有不同基因型的参与者进行了全面的眼科检查以及其他全身检查。基因评估显示,该家庭的先证者携带了两个从父亲遗传而来的该基因新变异,一个错义变异(c.9032G>A;p.Arg3011Lys)和一个新的剪接变异(c.2909-2A>T),它们与DBS患者的典型临床特征密切相关。因此,在本文中我们首次报道了该基因中导致DBS的两个新的复合杂合变异。我们的研究扩展了该基因相关DBS的基因型谱,更好地帮助医生对DBS进行预测、诊断和基因治疗。